asciminib
Selected indexed studies
- Asciminib in Newly Diagnosed Chronic Myeloid Leukemia. (N Engl J Med, 2024) [PMID:38820078]
- Asciminib. (, 2012) [PMID:37956234]
- Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. (Leukemia, 2023) [PMID:36717654]
_Worker-drafted node — pending editorial review._
Connections
asciminib is a side effect of
Sources
- Asciminib in Newly Diagnosed Chronic Myeloid Leukemia. (2024) pubmed
- Asciminib. (2012) pubmed
- Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. (2023) pubmed
- Asciminib. (2006) pubmed
- Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. (2019) pubmed
- A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. (2021) pubmed
- Development of asciminib, a novel allosteric inhibitor of BCR-ABL1. (2022) pubmed
- Asciminib for Philadelphia chromosome-positive leukemias. (2025) pubmed
- Asciminib: First Approval. (2022) pubmed
- Asciminib for chronic myeloid leukaemia: Next questions. (2022) pubmed